Tissue factor residues that putatively interact with membrane phospholipids. [PDF]
PLoS ONE, 2014 Blood clotting is initiated by the two-subunit enzyme consisting of the plasma protease, factor VIIa (the catalytic subunit), bound to the integral membrane protein, tissue factor (the regulatory subunit).
Ke Ke, Jian Yuan, James H Morrissey
doaj +1 more source
Medical Journal Armed Forces India, 2009 Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of hemophilic patients with inhibitors and then used successfully for treating hemorrhages in patients with acquired hemophilia. In the last few years, along with the improvement in the knowledge of its mechanisms of action, rFVIIa has also been used with benefit as a “
P, Kinra, H, Kumar
openaire +2 more sources
Inhibitors of Factor VIIa/Tissue Factor [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2007 The formation of the proteolytic complex composed of the serine protease Factor VIIa and the cell-associated glycoprotein tissue factor (FVIIa/TF) initiates a cascade of amplified zymogen activation reactions leading to thrombus formation. The critical role of the coagulation cascade in pathological thrombosis has been the basis for significant efforts
Rebecca A, Shirk, George P, Vlasuk
openaire +2 more sources
Haematologica, 2015 Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon +5 more
doaj +1 more source
Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression [PDF]
, 2016 BackgroundDespite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear.MethodsIn this study the upregulation of TF release upon ...
A Bharthuar +57 more
core +2 more sources
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity [PDF]
, 2017 Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea.
Bhatta, Puspanjali +12 more
core +2 more sources
Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves β1-integrin and extracellular signal regulated kinase activation [PDF]
, 2010 Objective: Increased levels of circulating tissue factor (TF) in the form of microparticles increase the risk of thrombosis. However, any direct influence of microparticle-associated TF on vascular endothelial cell proliferation is not known.
Collier, Mary E. W., Ettelaie, Camille
core +2 more sources
Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity [PDF]
, 2015 The complex of coagulation factor VIIa (FVIIa), a trypsin-like serine protease, and membrane-bound tissue factor (TF) initiates blood coagulation upon vascular injury.
Gandhi, Prafull S +7 more
core +1 more source
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Clinics and Practice, 2015 Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial
Shadi Yaghi +4 more
doaj +1 more source